Minutes of the twelfth meeting of the UK Haemophilia Centre Directors on 9 October 1981. Shows consensus that commercial concentrate be purchased in bulk. An increase in commercial factor usage is also reported along with a higher number of deaths (attributed to better reporting from centres). Dr Chanaran (absent) also submits that the manufacture of factor VIII be handled in toto by the pharmaceutical industry which was dismissed, discusses the estimated annual requirements of factor VIII as well as an active program of hepatitis reduction.